Anaveon

Anaveon was founded in December 2017 by two leading experts in the field of immunotherapy: Onur Boyman, professor and chairman in the Department of Immunology at the University of Zurich and a recognised IL-2 biology expert, and Andreas Katopodis, previously director at the Autoimmunity, Transplantation & Inflammation Group at the Novartis Institutes for BioMedical Research. UZH Spin-Off Anaveon was founded with initial seed capital from the UZH Life Sciences Fund which will convert in the Series A financing and additional funding from BaseLaunch, a healthcare accelerator operated by BaselArea.swiss.